Variable number of tandem repeats polymorphism in parathyroid hormone-related protein as predictor of peak bone mass in young healthy Finnish males

European Journal of Endocrinology

Volumn 158, Issue 5, 2008, Pages 755-764

  Gupta, Ajay ^a   Välimäki, Ville Valtteri ^a   Välimäki, Matti J ^b   Löyttyniemi, Eliisa ^c   Richard, Marilyn ^a   Bukka, Prasanna L ^d   Goltzman, David ^e   Karaplis, Andrew C ^d  

^a Osta Biotechnologies Inc   (Canada)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GENOMIC DNA; PARATHYROID HORMONE RELATED PROTEIN;

ADULT; ALLELE; ARTICLE; BONE DENSITY; BONE MASS; CALCANEUS; CORRELATION ANALYSIS; DNA EXTRACTION; ELECTROPHORETIC MOBILITY; FINLAND; GENE AMPLIFICATION; GENETIC ASSOCIATION; HIP; HUMAN; HUMAN EXPERIMENT; LIFESTYLE; LUMBAR SPINE; MALE; MULTIPLE REGRESSION; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; QUANTITATIVE ANALYSIS; TRANSCRIPTION REGULATION; VARIABLE NUMBER OF TANDEM REPEAT;

ADOLESCENT; ADULT; ALLELES; ANIMALS; BASE SEQUENCE; BONE DENSITY; CERCOPITHECUS AETHIOPS; COS CELLS; FINLAND; HUMANS; LUMBAR VERTEBRAE; MALE; MOLECULAR SEQUENCE DATA; OSTEOBLASTS; OSTEOPOROSIS; PARATHYROID HORMONE-RELATED PROTEIN; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TANDEM REPEAT SEQUENCES; VARIATION (GENETICS);

EID: 43149102669     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0886     Document Type: Article

References (46)

1. Ross PD. Osteoporosis. Frequency, consequences, and risk factors. Archives of Internal Medicine 1996 156 1399-1411.
2. Cauley JA, Thompson DE, Ensrud KC, Scott JC & Black D. Risk of mortality following clinical fractures. Osteoporosis International 2000 11 556-561.
3. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN & Eberl S. Genetic determinants of bone mass in adults. A twin study. Journal of Clinical Investigation 1987 80 706-710.
4. Ralston SH. Genetics of osteoporosis. Reviews in Endocrine and Metabolic Disorders 2001 2 13-21.
5. Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VL, Kronenberg HM & Mulligan RC. Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes and Development 1994 8 277-289.
6. Amizuka N, Warshawsky H, Henderson JE, Goltzman D & Karaplis AC. Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. Journal of Cell Biology 1994 126 1611-1623.
7. Amizuka N, Karaplis AC, Henderson JR, Warshawsky H, Lipman ML, Matsuki Y, Ejiri S, Tanaka M, Izumi N, Ozawa H & Goltzman D. Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Developmental Biology 1996 175 166-176.
8. Miao D, He B, Jiang Y, Kobayashi T, Soroceanu MA, Zhao J, Su H, Tong X, Amizuka N, Gupta A, Genant RK, Kronenberg HM, Goltzman D, Karaplis AC & Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. Journal of Clinical Investigation 2005 115 2402-2411.
9. Schipani E, Kruse K & Juppner H. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 1995 268 98-100.
10. Jobert AS, Zhang P, Couvineau A, Bonaventure J, Roume J, Le Merrer M & Silve C. Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. Journal of Clinical Investigation 1998 102 34-40.
11. Karaplis AC, He B, Nguyen MT, Young ID, Semeraro D, Ozawa H & Amizuka N. Inactivating mutation in the human parathyroid hormone receptor type 1 gene in Blomstrand chondrodysplasia. Endocrinology 1998 139 5255-5258.
12. Yasuda T, Banville D, Hendy GN & Goltzman D. Characterization of the human parathyroid hormone-like peptide gene. Functional and evolutionary aspects. Journal of Biological Chemistry 1989 264 7720-7725.
13. Pausova Z, Morgan K, Fujiwara TM, Bourdon J, Goltzman D & Hendy GN. Molecular characterization of an intragenic minisatellite (VNTR) polymorphism in the human parathyroid hormone-related peptide gene in chromosome region 12pl2.1-pll.2. Genomics 1993 17 243-244.
14. Valimaki MJ, Karkkainen M, Lamberg-Allardt C, Laitinen K, Alhava E, Heikkinen J, Impivaara O, Makela P, Palmgren J & Seppanen R. Exercise, smoking, and calcium intake during adolescence and early adulthood as determinants of peak bone mass. Cardiovascular Risk in Young Finns Study Group. BMJ 1994 309 230-235.
15. Panda DK, Miao D, Bolivar I, Li J, Huo R, Hendy GN & Goltzman D. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. Journal of Biological Chemistry 2004 279 16754-16766.
16. Valimaki VV, Alfthan H, Lehmuskallio E, Loyttyniemi E, Sahi T, Stenman UH, Suominen H & Valimaki MJ. Vitamin D status as a determinant of peak bone Tnass in young Finnish men. Journal of Clinical Endocrinology and Metabolism 2004 89 76-80.
17. Lewiecki EM. Premenopausal bone health assessment. Current Rheumatology Reports 2005 7 46-52.
18. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN & Eisman JA. Prediction of bone density from vitamin D receptor alleles. Nature 1994 367 284-287.
19. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P & Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. American Journal of Human Genetics 2001 68 577-589.
20. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D & Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Human Molecular Genetics 2001 10 537-543.
21. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, Lacombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, Van Den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR & Warman ML. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001 107 513-523.
22. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, Fitzgerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, Mcguire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR & Johnson ML. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. American Journal of Human Genetics 2002 70 11-19.
23. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K & Lifton RP. High bone density due to a mutation in LDL-receptor-related protein 5. New England Journal of Medicine 2002 346 1513-1521.
24. Hartikka H, Makitie O, Mannikko M, Doria AS, Daneman A, Cole WG, Ala-Kokko L & Sochett EB. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. Journal of Bone and Mineral Research 2005 20 783-789.
25. Grant SF, Reid DM, Blake G, Herd R, Fogelman I & Ralston SH. Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nature Genetics 1996 14 203-205.
26. Uitterlinden AG, Arp PP, Paeper BW, Charmley P, Proll S, Rivadeneira F, Fang Y, Van Meurs JB, Britschgi TB, Latham JA, Schatzman RC, Pols HA & Brunkow ME. Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. American Journal of Human Genetics 2004 75 1032-1045.
27. Koay MA, Woon PY, Zhang Y, Miles LJ, Duncan EL, Ralston SH, Compston JE, Cooper C, Keen R & Langdahl Et A. Influence of LRP5 polymorphisms on normal variation in BMD. Journal of Bone and Mineral Research 2004 19 1619-1627.
28. Ferrari SL, Deutsch S, Choudhury U, Chevalley T, Bonjour J-P, Dermitzakis ET, Rizzoli R & Antonarakis SE. Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. American Journal of Human Genetics 2004 74 866-875.
29. Saarinen A, Valimaki VV, Valimaki MJ, Loyttyniemi E, Auro K, Uusen P, Kuris M, Lehesjoki AE & Makitie O. The A1330V polymorphism of the low-density lipoprotein receptor-related protein 5 gene (LRP5) associates with low peak bone mass in young healthy men. Bone 2007 40 1006-1012.
30. Välimäki VV, Piippo K, Välimäki S, Löyttyniemi E, Kontula K & Välimäki MJ. The relation of the XbaI and PvuII polymorphisms of the estrogen receptor gene and the CAG repeat polymorphism of the androgen receptor gene to peak bone mass and bone turnover rate among young healthy men. Osteoporosis International 2005 16 1633-1640.
31. Enattah N, Välimäki VV, Välimäki MJ, Löyttyniemi E, Sahi T & Järvela I. Molecularly defined lactose malabsorption, peak bone mass and bone turnover rate in young Finnish men. Calcified Tissue International 2004 75 488-493.
32. Styrkarsdottir U, Cazier JB, Kong A, Rolfsson O, Larsen H, Bjarnadottir E, Johannsdottir VD, Sigurdardottir MS, Bagger Y, Christiansen C, Reynisdottir I, Grant SF, Jonasson K, Frigge ML, Gulcher JR, Sigurdsson G & Stefansson K. Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biology 2003 1 E69.
33. Gogos JA, Hsu T, Bolton J & Kafatos FC. Sequence discrimination by alternatively spliced isoforms of a DNA binding zinc finger domain. Science 1992 257 1951-1955.
34. Duncan EL, Brown MA, Sinsheimer J, Bell J, Carr AJ, Wordsworth BP & Wass JA. Suggestive linkage of the parathyroid receptor type 1 to osteoporosis. Journal of Bone and Mineral Research 1999 14 1993-1999.
35. Minagawa M, Yasuda T, Watanabe T, Minamitani K, Takahashi Y, Goltzman D, White JH, Hendy GN & Kohno Y. Association between AAAG repeat polymorphism in the P3 promoter of the human parathyroid hormone (PTH)/ PTH-related peptide receptor gene and adult height, urinary pyridinoline excretion, and promoter activity. Journal of Clinical Endocrinology and Metabolism 2002 87 1791-1796.
36. Hosoi T, Miyao M, Inoue S, Hoshino S, Shiraki M, Orimo H & Ouchi Y. Association study of parathyroid hormone gene polymorphism and bone mineral density in Japanese postmenopausal women. Calcified Tissue International 1999 64 205-208.
37. Xue Y, Karaplis AC, Hendy GN, Goltzman D & Miao D. Genetic models show that parathyroid hormone and 1,25-dihydroxyvitamin D3 play distinct and synergistic roles in postnatal mineral ion homeostasis and skeletal development. Human Molecular Genetics 2005 14 1515-1528.
38. Miao D, He B, Karaplis AC & Goltzman D. Parathyroid hormone is essential for normal fetal bone formation. Journal of Clinical Investigation 2002 109 1173-1182.
39. Omi T, Kumada M, Kamesaki T, Okuda H, Munkhtulga L, Yanagisawa Y, Utsumi N, Gotoh T, Hata A, Soma M, Umemura S, Ogihara T, Takahashi N, Tabara Y, Shimada K, Marto H, Kajii E, Miki T & Iwamoto S. An intronic variable number of tandem repeat polymorphisms of the cold-induced autoinflammatory syndrome 1 (CIAS1) gene modifies gene expression and is associated with essential hypertension. European Journal of Human Genetics 2006 14 1295-1305.
40. Mackenzie A & Quinn J. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. PNAS 1999 96 15251-15255.
41. Keller H & Kneissel M. SOST is a target gene for PTH in bone. Bone 2005 37 148-158.
42. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'brien CA, Manolagas SC & Jilka RL. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005 146 4577-4583.
43. Glass DA, II, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, Mcmahon AP, Lang RA & Karsenty G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental Cell 2005 8 751-764.
44. Thorsby PM, Berg JP & Birkeland KI. Insulin gene variable number of tandem repeats is associated with increased fat mass during adolescence in non-obese girls. Scandinavian Journal of Clinical and Laboratory Investigation 2005 65 163-168.
45. Simsek M, Al-Sharbati M, Al-Adawi S, Ganguly SS & Lawatia K. Association of the risk allele of dopamine transporter gene (DAT1 × 10) in Omani male children with attention-deficit hyperactivity disorder. Clinical Biochemistry 2005 38 739-742.
46. Ferrari SL, Deutsch S & Antonarakis SE. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass. Current Opinion in Lipidology 2005 16 207-214.